Cash From Operating Activities - Prostatype Genomics AB (STO:PROGEN) - Alpha Spread
P

Prostatype Genomics AB
STO:PROGEN

Watchlist Manager
Prostatype Genomics AB
STO:PROGEN
Watchlist
Price: 0.019 SEK -7.32% Market Closed
Market Cap: 18.8m SEK
Have any thoughts about
Prostatype Genomics AB?
Write Note

Prostatype Genomics AB
Cash from Operating Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Prostatype Genomics AB
Cash from Operating Activities Peer Comparison

Comparables:
BIOG B
BONEX
VITR
SOBI
BIOA B

Competitive Cash from Operating Activities Analysis
Latest Figures & CAGR of Competitors

Company Cash from Operating Activities CAGR 3Y CAGR 5Y CAGR 10Y
P
Prostatype Genomics AB
STO:PROGEN
Cash from Operating Activities
-kr29.1m
CAGR 3-Years
-26%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Biogaia AB
STO:BIOG B
Cash from Operating Activities
kr426m
CAGR 3-Years
24%
CAGR 5-Years
18%
CAGR 10-Years
N/A
Bonesupport Holding AB
STO:BONEX
Cash from Operating Activities
-kr20.6m
CAGR 3-Years
38%
CAGR 5-Years
36%
CAGR 10-Years
N/A
Vitrolife AB
STO:VITR
Cash from Operating Activities
kr819m
CAGR 3-Years
15%
CAGR 5-Years
19%
CAGR 10-Years
21%
Swedish Orphan Biovitrum AB (publ)
STO:SOBI
Cash from Operating Activities
kr6.7B
CAGR 3-Years
17%
CAGR 5-Years
18%
CAGR 10-Years
55%
BioArctic AB
STO:BIOA B
Cash from Operating Activities
kr309.7m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A

See Also

What is Prostatype Genomics AB's Cash from Operating Activities?
Cash from Operating Activities
-29.1m SEK

Based on the financial report for Dec 31, 2023, Prostatype Genomics AB's Cash from Operating Activities amounts to -29.1m SEK.

What is Prostatype Genomics AB's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 3Y
-26%

Over the last year, the Cash from Operating Activities growth was -5%. The average annual Cash from Operating Activities growth rates for Prostatype Genomics AB have been -26% over the past three years .

Back to Top